Ignite Creation Date:
2026-03-26 @ 3:17 PM
Ignite Modification Date:
2026-06-21 @ 6:26 AM
Study NCT ID:
NCT07446335
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-03-03
First Post:
2026-02-25
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma
Sponsor:
The First Affiliated Hospital of Zhengzhou University
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Esophageal Squamous Cell Carcinoma | View |
Keywords: